Related Experiment Video

Updated: Jul 16, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

[Multimodal Treatments for Spinal Cord Glioma: Up to Date]

Toshiki Endo1, Yoshiharu Takahashi, Taketo Nishizawa

  • 1Division of Neurosurgery, Tohoku Medical and Pharmaceutical University.

No Shinkei Geka. Neurological Surgery
|January 30, 2025
PubMed

Insights

This review covers diagnostic criteria and treatments for spinal malignant gliomas, including IDH-wildtype glioblastoma and H3-K27 altered diffuse midline gliomas. Current treatments show poor prognosis, but novel therapies offer hope.

Area of Science:

  • Neuro-oncology
  • Molecular pathology
  • Oncologic surgery

Context:

  • The World Health Organization 2021 classification redefines spinal malignant gliomas, emphasizing IDH-wildtype glioblastoma and H3-K27 altered diffuse midline gliomas.
  • Surgical resection of these tumors is inherently difficult due to their diffuse infiltration patterns.
  • The standard Stupp regimen (temozolomide and radiotherapy) offers limited survival benefits, with an average of 12 months.

Purpose:

  • To review current diagnostic criteria for spinal malignant gliomas based on the WHO 2021 classification.
  • To examine existing treatment strategies and their limitations.
  • To explore emerging therapeutic approaches for improved patient outcomes.

Summary:

  • The study details diagnostic criteria for IDH-wildtype glioblastoma and H3-K27 altered diffuse midline gliomas.
  • Current standard treatments, including the Stupp regimen, provide a poor prognosis.
  • Investigational therapies like photodynamic therapy, ONC201, and anlotinib show potential for improving outcomes.

Impact:

  • Highlights the need for advanced molecular profiling in spinal glioma diagnosis and treatment.
  • Underscores the potential of novel targeted therapies and photodynamic therapy.
  • Emphasizes the critical role of collaborative research in advancing the management of malignant spinal gliomas.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K
Surgical Transplantation of Tumor Cells into the Spinal Cord of Mice05:39

Surgical Transplantation of Tumor Cells into the Spinal Cord of Mice

Published on: December 27, 2024

343

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...